Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations.
Journal
JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
29
8
2020
pubmed:
29
8
2020
medline:
29
8
2020
Statut:
ppublish
Résumé
Alterations in DNA damage repair (DDR) genes occur in up to 25% of patients with metastatic castration-resistant prostate cancer (mCRPC) and may sensitize to platinum chemotherapy. We aimed to evaluate the efficacy of platinum-based chemotherapy in DDR-mutant (DDRmut) mCRPC. We assessed response to platinum chemotherapy based on DDR gene alteration status in men with mCRPC who underwent tumor and germline genomic profiling. Patients with deleterious alterations in a gene panel that included A total of 109 patients with mCRPC received platinum-based chemotherapy between October 2013 and July 2018. Sixty-four of 109 patients were taxane refractory and poly (ADP-ribose) polymerase inhibitor (PARPi) naïve. Within this subset, DDRmut was found in 16/64 patients (25%) and was associated with an increased likelihood of achieving a prostate-specific antigen (PSA) decline of 50% or more from baseline (PSA50; odds ratio, 7.0; 95% CI, 1.9 to 29.2). Time on platinum chemotherapy tended to be longer in the DDRmut group (median, 3.0 Patients with DDRmut disease had better response to platinum-based chemotherapy, suggesting that DDR status warrants prospective validation as a potential biomarker for patient selection. Responses to platinum chemotherapy were observed in
Identifiants
pubmed: 32856010
doi: 10.1200/po.19.00346
pmc: PMC7446522
mid: NIHMS1601277
doi:
Types de publication
Journal Article
Langues
eng
Pagination
355-366Subventions
Organisme : NCI NIH HHS
ID : P01 CA228696
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA092629
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Lancet Oncol. 2019 Oct;20(10):1432-1443
pubmed: 31515154
Cell. 2000 Jun 23;101(7):789-800
pubmed: 10892749
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Cancer Discov. 2019 Feb;9(2):210-219
pubmed: 30425037
J Mol Cell Biol. 2014 Dec;6(6):442-57
pubmed: 25404613
JAMA. 2017 Sep 5;318(9):825-835
pubmed: 28873162
Ann Oncol. 2016 Jun;27(6):975-984
pubmed: 27052650
Cancer. 2008 Feb 1;112(3):521-6
pubmed: 18085595
Clin Cancer Res. 2020 Jun 1;26(11):2487-2496
pubmed: 32086346
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28825054
J Natl Cancer Inst. 2012 May 2;104(9):670-81
pubmed: 22505474
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821
Clin Cancer Res. 2013 Jul 1;19(13):3621-30
pubmed: 23649003
JAMA Oncol. 2019 Apr 01;5(4):471-478
pubmed: 30589920
Nucleic Acids Res. 2017 May 5;45(8):4590-4605
pubmed: 28334891
J Clin Oncol. 2009 Nov 10;27(32):5431-8
pubmed: 19805692
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Clin Cancer Res. 2016 Aug 1;22(15):3764-73
pubmed: 26957554
Eur Urol. 2016 Jun;69(6):992-5
pubmed: 26724258
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
Cell. 1998 May 1;93(3):467-76
pubmed: 9590180
Eur Urol. 2019 Jan;75(1):184-192
pubmed: 30340782
Cancer. 2017 Sep 15;123(18):3532-3539
pubmed: 28608931
Ann Oncol. 2010 Feb;21(2):312-318
pubmed: 19633053
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Cell. 2015 Jul 16;162(2):454
pubmed: 28843286
J Biol Chem. 2012 Jan 27;287(5):3366-80
pubmed: 22167183